Constitutively active PKB increases development and activation status of CD34-derived pDCs in vivo. CD34⁺ HPCs were retrovirally transduced with myrPKB or a control vector. Day 3 unsorted cells were intravenously injected into β2-microglobulin^−/− NOD/SCID mice. Six weeks after transplantation, bone marrow cells were analyzed for the expression of eGFP, CD123, BDCA-2, and CD86. The presence of CD123⁺BDCA-2⁺ human pDCs within the eGFP⁺ fraction and the expression of CD86 by eGFP⁺CD123⁺BDCA-2⁺ human pDCs was determined. (A) Shown are representative FACS plots gated on eGFP⁺ cells and percentage CD123⁺BDCA-2⁺ human pDCs within the eGFP⁺ population per mouse (control, n = 4; myrPKB, n = 5). (B) Specific CD86 staining of eGFP⁺ human pDCs was calculated by subtracting MFI of the isotype control from the MFI measured for CD86. Expression in different experiments was standardized to control per experiment. Shown are representative FACS plots gated on eGFP⁺ human pDCs and standardized CD86 expression by eGFP⁺ human pDCs per mouse (control, n = 3; myrPKB, n = 3). Numbers in the FACS plots indicate the specific staining calculated for the experiment shown. *P < .05, Mann-Whitney U test.